TR200103488T2 - Geliştirilmiş farmasötik formülasyonlar. - Google Patents

Geliştirilmiş farmasötik formülasyonlar.

Info

Publication number: TR200103488T2
Authority: TR; Turkey
Prior art keywords: pharmaceutical formulations; improved pharmaceutical; improved; ethanol; contain
Prior art date: 1999-06-04

Application number

TR2001/03488T

Other languages

English (en)

Turkish (tr)

Inventor

A. Alani Laman

Ghosh Soumojeet

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-04

Filing date

2000-05-25

Publication date

2002-04-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23269615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200103488(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-05-25 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

2002-04-22 Publication of TR200103488T2 publication Critical patent/TR200103488T2/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
108010010369 HIV Protease Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
235000014113 dietary fatty acids Nutrition 0.000 abstract 1
229930195729 fatty acid Natural products 0.000 abstract 1
239000000194 fatty acid Substances 0.000 abstract 1
150000004665 fatty acids Chemical class 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000008018 melting Effects 0.000 abstract 1
238000002844 melting Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TR2001/03488T 1999-06-04 2000-05-25 Geliştirilmiş farmasötik formülasyonlar. TR200103488T2 (tr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US32582699A	1999-06-04	1999-06-04

Publications (1)

Publication Number	Publication Date
TR200103488T2 true TR200103488T2 (tr)	2002-04-22

Family

ID=23269615

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TR2001/03488T TR200103488T2 (tr)	1999-06-04	2000-05-25	Geliştirilmiş farmasötik formülasyonlar.

Country Status (32)

Country	Link
EP (2)	EP1183026B1 (de)
JP (1)	JP4753511B2 (de)
KR (1)	KR100815412B1 (de)
CN (2)	CN100418527C (de)
AR (2)	AR032586A1 (de)
AT (2)	ATE332132T1 (de)
AU (1)	AU778198B2 (de)
BG (1)	BG65445B1 (de)
BR (1)	BR0007294A (de)
CA (1)	CA2371109C (de)
CL (1)	CL2008003491A1 (de)
CO (1)	CO5160323A1 (de)
CY (2)	CY1105237T1 (de)
CZ (1)	CZ301308B6 (de)
DE (2)	DE60042092D1 (de)
DK (2)	DK1733725T4 (de)
ES (2)	ES2265946T3 (de)
HU (1)	HU229501B1 (de)
IL (3)	IL146025A0 (de)
MX (1)	MXPA01012478A (de)
MY (1)	MY127908A (de)
NO (1)	NO328968B1 (de)
NZ (1)	NZ515016A (de)
PL (1)	PL197671B1 (de)
PT (2)	PT1183026E (de)
SA (1)	SA00210237B1 (de)
SI (2)	SI1733725T2 (de)
SK (2)	SK286305B6 (de)
TR (1)	TR200103488T2 (de)
TW (1)	TWI244390B (de)
WO (1)	WO2000074677A2 (de)
ZA (1)	ZA200108641B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY121765A (en) *	1998-07-20	2006-02-28	Abbott Lab	Polymorph of ritonavir
PT1183026E (pt) *	1999-06-04	2006-11-30	Abbott Lab	Formulações farmacêuticas melhoradas incluindo ritonavir
US7141593B1 (en)	1999-06-04	2006-11-28	Abbott Laboratories	Pharmaceutical formulations
US7364752B1 (en)	1999-11-12	2008-04-29	Abbott Laboratories	Solid dispersion pharamaceutical formulations
EP1175205B1 (de)	1999-11-12	2006-06-14	Abbott Laboratories	Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
ES2676151T3 (es) *	2000-01-19	2018-07-17	Abbvie Inc.	Formulaciones farmacéuticas mejoradas
MXPA03010771A (es) *	2001-05-25	2004-07-01	Abbott Lab	Capsulas elasticas blandas que comprenden ritonavir y/o lopinavir.
US20050048112A1 (en)	2003-08-28	2005-03-03	Jorg Breitenbach	Solid pharmaceutical dosage form
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
US20070219243A1 (en) *	2005-12-30	2007-09-20	Kearney Brian P	Method for improving the pharmacokinetics of HIV integrase inhibitors
NO347119B1 (no) *	2006-07-07	2023-05-15	Gilead Sciences Inc	Modulatorer av farmakokinetikkegenskaper til terapeutika
AU2015234299B2 (en) *	2006-07-07	2017-03-09	Gilead Sciences, Inc.	Modulators of pharmacokinetic properties of therapeutics
AU2015258296B2 (en) *	2006-07-07	2017-08-17	Gilead Sciences, Inc.	Modulators of pharmacokinetic properties of therapeutics
AU2013204805C1 (en) *	2006-07-07	2017-03-09	Gilead Sciences, Inc.	Modulators of pharmacokinetic properties of therapeutics
KR101477822B1 (ko) *	2006-07-07	2015-01-02	길리애드 사이언시즈, 인코포레이티드	치료제의 약동학 특성의 모듈레이터
WO2008067164A2 (en)	2006-11-15	2008-06-05	Abbott Laboratories	Solid pharmaceutical dosage formulations
AU2015204378B2 (en) *	2007-02-23	2017-03-09	Gilead Sciences, Inc.	Modulators of pharmacokinetic properties of therapeutics
PT3150586T (pt) *	2007-02-23	2020-03-31	Gilead Sciences Inc	Moduladores de propriedades farmacocinéticas de agentes terapêuticos
AU2013204817B2 (en) *	2007-02-23	2015-05-07	Gilead Sciences, Inc.	Modulators of pharmacokinetic properties of therapeutics
ME02628B (de)	2007-02-23	2017-06-20	Gilead Sciences Inc	Modulatoren der pharmakokinetischen Eigenschaften von Therapeutika
KR20100040896A (ko) *	2007-07-06	2010-04-21	길리애드 사이언시즈, 인코포레이티드	치료제의 약동학적 특성의 조절제
PT2231628E (pt)	2008-01-04	2015-12-29	Gilead Sciences Inc	Inibidores de citocromo p450
UA108738C2 (uk) *	2009-04-03	2015-06-10		Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5696270A (en) *	1989-05-23	1997-12-09	Abbott Laboratories	Intermediate for making retroviral protease inhibiting compounds
GB8927913D0 (en) *	1989-12-11	1990-02-14	Hoffmann La Roche	Amino acid derivatives
US5413999A (en) *	1991-11-08	1995-05-09	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
IL110752A (en) *	1993-09-13	2000-07-26	Abbott Lab	Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) *	1993-10-01	1996-09-24	Abbott Laboratories	Pharmaceutical composition
IL111991A (en) *	1994-01-28	2000-07-26	Abbott Lab	Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
DE69535127T2 (de) *	1994-03-18	2007-02-15	Supernus Pharmaceuticals, Inc.	Emulgierte arzneistoffabgabesysteme
DE4431489A1 (de) *	1994-09-03	1996-03-07	Heidelberger Baustofftech Gmbh	Schnellhärtende aminosilanvernetzende Silikonmassen
US5567823A (en) *	1995-06-06	1996-10-22	Abbott Laboratories	Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) *	1995-06-29	2000-03-14	Abbott Laboratories	Method for improving pharmacokinetics
US5914332A (en) *	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
CA2238977A1 (en) *	1995-12-13	1997-06-19	Abbott Laboratories	Retroviral protease inhibiting compounds
ZA9710071B (en) *	1996-11-21	1998-05-25	Abbott Lab	Pharmaceutical composition.
MY121765A (en) *	1998-07-20	2006-02-28	Abbott Lab	Polymorph of ritonavir
PT1183026E (pt) *	1999-06-04	2006-11-30	Abbott Lab	Formulações farmacêuticas melhoradas incluindo ritonavir

2000
- 2000-05-25 PT PT00937743T patent/PT1183026E/pt unknown
- 2000-05-25 EP EP00937743A patent/EP1183026B1/de not_active Revoked
- 2000-05-25 PL PL351943A patent/PL197671B1/pl unknown
- 2000-05-25 TR TR2001/03488T patent/TR200103488T2/xx unknown
- 2000-05-25 CN CNB008083207A patent/CN100418527C/zh not_active Expired - Lifetime
- 2000-05-25 CZ CZ20014293A patent/CZ301308B6/cs not_active IP Right Cessation
- 2000-05-25 SK SK1720-2001A patent/SK286305B6/sk not_active IP Right Cessation
- 2000-05-25 CN CN2008101301744A patent/CN101361723B/zh not_active Expired - Lifetime
- 2000-05-25 JP JP2001501214A patent/JP4753511B2/ja not_active Expired - Lifetime
- 2000-05-25 HU HU0201591A patent/HU229501B1/hu not_active IP Right Cessation
- 2000-05-25 DE DE60042092T patent/DE60042092D1/de not_active Expired - Lifetime
- 2000-05-25 EP EP06114684A patent/EP1733725B2/de not_active Revoked
- 2000-05-25 PT PT06114684T patent/PT1733725E/pt unknown
- 2000-05-25 SK SK5083-2007A patent/SK287185B6/sk not_active IP Right Cessation
- 2000-05-25 DK DK06114684.1T patent/DK1733725T4/da active
- 2000-05-25 DE DE60029219T patent/DE60029219T2/de not_active Expired - Lifetime
- 2000-05-25 AU AU52877/00A patent/AU778198B2/en not_active Revoked
- 2000-05-25 IL IL14602500A patent/IL146025A0/xx unknown
- 2000-05-25 MX MXPA01012478A patent/MXPA01012478A/es active IP Right Grant
- 2000-05-25 DK DK00937743T patent/DK1183026T3/da active
- 2000-05-25 SI SI200031028T patent/SI1733725T2/sl unknown
- 2000-05-25 AT AT00937743T patent/ATE332132T1/de active
- 2000-05-25 KR KR1020017015577A patent/KR100815412B1/ko not_active Ceased
- 2000-05-25 NZ NZ515016A patent/NZ515016A/xx not_active IP Right Cessation
- 2000-05-25 ES ES00937743T patent/ES2265946T3/es not_active Expired - Lifetime
- 2000-05-25 ES ES06114684T patent/ES2324549T5/es not_active Expired - Lifetime
- 2000-05-25 WO PCT/US2000/014342 patent/WO2000074677A2/en not_active Ceased
- 2000-05-25 BR BR0007294-0A patent/BR0007294A/pt not_active Application Discontinuation
- 2000-05-25 CA CA2371109A patent/CA2371109C/en not_active Expired - Lifetime
- 2000-05-25 SI SI200030880T patent/SI1183026T1/sl unknown
- 2000-05-25 AT AT06114684T patent/ATE429224T1/de active
- 2000-05-31 MY MYPI20002425A patent/MY127908A/en unknown
- 2000-05-31 CO CO00040645A patent/CO5160323A1/es unknown
- 2000-06-02 AR ARP000102748A patent/AR032586A1/es not_active Application Discontinuation
- 2000-06-03 TW TW089110863A patent/TWI244390B/zh active
- 2000-07-17 SA SA00210237A patent/SA00210237B1/ar unknown
2001
- 2001-10-18 IL IL146025A patent/IL146025A/en active IP Right Grant
- 2001-10-19 ZA ZA200108641A patent/ZA200108641B/en unknown
- 2001-11-20 NO NO20015670A patent/NO328968B1/no not_active Application Discontinuation
- 2001-12-19 BG BG106239A patent/BG65445B1/bg unknown
2006
- 2006-09-21 CY CY20061101354T patent/CY1105237T1/el unknown
2007
- 2007-12-12 AR ARP070105573A patent/AR064309A2/es not_active Application Discontinuation
2008
- 2008-11-24 CL CL2008003491A patent/CL2008003491A1/es unknown
2009
- 2009-06-29 CY CY20091100675T patent/CY1109135T1/el unknown
2011
- 2011-11-29 IL IL216686A patent/IL216686A/en active IP Right Grant

Also Published As

Publication number	Publication date
WO2000074677A2 (en)	2000-12-14
CA2371109C (en)	2011-04-26
NZ515016A (en)	2004-02-27
PT1733725E (pt)	2009-06-30
EP1733725B1 (de)	2009-04-22
BG65445B1 (bg)	2008-08-29
ATE332132T1 (de)	2006-07-15
IL146025A (en)	2012-04-30
IL216686A0 (en)	2012-01-31
DK1733725T3 (da)	2009-08-03
CN101361723B (zh)	2013-11-06
MXPA01012478A (es)	2003-10-14
KR20020011994A (ko)	2002-02-09
HUP0201591A2 (en)	2002-09-28
HK1045804A1 (en)	2002-12-13
NO20015670L (no)	2001-11-20
CA2371109A1 (en)	2000-12-14
PL197671B1 (pl)	2008-04-30
AU778198B2 (en)	2004-11-25
ZA200108641B (en)	2003-01-20
CY1105237T1 (el)	2010-03-03
DK1183026T3 (da)	2006-11-06
NO328968B1 (no)	2010-06-28
JP2003501386A (ja)	2003-01-14
ATE429224T1 (de)	2009-05-15
EP1183026A2 (de)	2002-03-06
BR0007294A (pt)	2002-08-27
MY127908A (en)	2006-12-29
JP4753511B2 (ja)	2011-08-24
ES2265946T3 (es)	2007-03-01
DE60029219D1 (de)	2006-08-17
HU229501B1 (hu)	2014-01-28
NO20015670D0 (no)	2001-11-20
AU5287700A (en)	2000-12-28
TWI244390B (en)	2005-12-01
SK287185B6 (sk)	2010-02-08
DK1733725T4 (da)	2012-09-17
CN101361723A (zh)	2009-02-11
CL2008003491A1 (es)	2009-03-06
SI1183026T1 (sl)	2006-10-31
CO5160323A1 (es)	2002-05-30
WO2000074677A3 (en)	2001-02-22
SK286305B6 (en)	2008-07-07
ES2324549T5 (es)	2012-10-31
SI1733725T1 (sl)	2009-08-31
DE60042092D1 (de)	2009-06-04
EP1733725A1 (de)	2006-12-20
DE60029219T2 (de)	2007-06-28
AR064309A2 (es)	2009-03-25
HUP0201591A3 (en)	2002-10-28
PL351943A1 (en)	2003-07-14
SI1733725T2 (sl)	2012-10-30
SA00210237B1 (ar)	2006-11-07
IL216686A (en)	2014-01-30
PT1183026E (pt)	2006-11-30
AR032586A1 (es)	2003-11-19
CN100418527C (zh)	2008-09-17
CY1109135T1 (el)	2014-07-02
ES2324549T3 (es)	2009-08-10
EP1733725B2 (de)	2012-08-08
KR100815412B1 (ko)	2008-03-20
CN1353607A (zh)	2002-06-12
IL146025A0 (en)	2002-07-25
EP1183026B1 (de)	2006-07-05
CZ301308B6 (cs)	2010-01-06
CZ20014293A3 (cs)	2002-03-13
BG106239A (en)	2002-08-30
SK17202001A3 (sk)	2002-03-05

Publication	Publication Date	Title
BG106239A (en)	2002-08-30	Improved pharmaceutical formulations
TR200103186T2 (tr)	2002-04-22	MEK enzimlerinin inhibitörleri olarak kinolin türevleri
AP2003002916A0 (en)	2003-12-31	HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
DE69718668D1 (de)	2003-02-27	Flüssige zusammensetzung, hiv protease inhibitoren und c12-c18 fettsaure enthaltend
DK1299348T3 (da)	2008-07-28	Forbindelser og sammensætninger til levering af aktive midler
AU3652102A (en)	2002-06-11	Compounds and their uses
DK1157037T3 (da)	2003-11-24	GCSF-konjugater
HK1039110A1 (zh)	2002-04-12	以新颖的合成物及组分作为蛋白酶抑制剂
EA200100972A1 (ru)	2002-02-28	Новые соединения и композиции как ингибиторы протеаз
ATE486587T1 (de)	2010-11-15	Formulierungen zur oralen verabreichung von wirkstoffen
CY1120408T1 (el)	2019-07-10	Βελτιωμενες φαρμακοτεχνικες μορφες
TR200200494T2 (tr)	2003-02-21	Yağlı asit sintazı inhibitörleri.
MY117392A (en)	2004-06-30	Monocyclic compounds with four bifunctional residues having nk-2 antagonist action
IT1298442B1 (it)	2000-01-10	Composizioni orali a basso dosaggio di proteine citotossiche
ATE317384T1 (de)	2006-02-15	Lta4 hydrolase-hemmer
IT1306200B1 (it)	2001-05-30	Composizioni vulcanizzabili di fluoroelastomeri.
PL366625A1 (en)	2005-02-07	Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
EP1452522A3 (de)	2005-02-09	Neue Verbindungen und Zusammensetzungen als Protease Inhibitore
GR1003969B (el)	2002-08-14	Σταθερα φαρμακευτικα διαλυματα νιμεσουλιδης.
HK1067363A (en)	2005-04-08	Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
HN2000000089A (es)	2001-02-16	Polimorfos de un diclohidrato cristalino de azobiciclo (2,2,2) oct - 3 - ilamina y sus composiciones farmaceuticas.
ECSP003326A (es)	2000-10-24	1,2,3,4,5,6 - hexahidro- 2,6 - metano - 3 - benzazocin - 10 - oles sustituidos con n- (5- fenil- tetahidrofuranil) metilo y n-(6-feniltetrahidropiranil) metilo; procedimientos para prepararlos y su empleo como composiciones farmaceuticas